MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma and Hodgkin lymphoma as well.
Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.
The [R]-MINE regimen consists of:
- (R)ituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones;
- (M)esna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
- (I)fosfamide - an alkylating antineoplastic agent from oxazafosforine group;
- (N)ovantrone - a synthetic antracycline analogue (antraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis);
- (E)toposide - a topoisomerase inhibitor.
References
MINE (chemotherapy) Wikipedia(Text) CC BY-SA